Drugs / Enzomenib
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07444268 | Mar → Aug 2026 overdue | hematopoietic and lymphoid cell neoplasm | Sumitomo Pharma America, Inc. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04988555 | Feb 2022 → Jun 2027 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | Sumitomo Pharma America, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enzomenib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04988555 ↗ |
| Known as | DSP-5336 | “A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)” NCT04988555 ↗ |
| Modality | Small molecule | — CHEMBL5314915 ↗ |
| Route | Oral | “single oral administration” NCT07444268 ↗ |